Rockefeller Capital Management L.P. Has $1.04 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Rockefeller Capital Management L.P. lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 86.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,394 shares of the medical device company's stock after selling 100,313 shares during the quarter. Rockefeller Capital Management L.P.'s holdings in DexCom were worth $1,042,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of DXCM. Jennison Associates LLC lifted its stake in DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock worth $464,782,000 after purchasing an additional 6,544,102 shares during the period. Westfield Capital Management Co. LP lifted its position in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock worth $190,532,000 after buying an additional 876,739 shares during the period. Canada Pension Plan Investment Board boosted its stake in DexCom by 189.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company's stock valued at $75,471,000 after buying an additional 435,401 shares in the last quarter. Intech Investment Management LLC grew its position in DexCom by 2,083.0% in the third quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company's stock valued at $25,967,000 after acquiring an additional 369,587 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its position in DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock valued at $276,538,000 after acquiring an additional 353,019 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on DXCM. Royal Bank of Canada reduced their target price on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Wells Fargo & Company lifted their target price on DexCom from $80.00 to $90.00 and gave the company an "overweight" rating in a research note on Friday, October 25th. Piper Sandler restated an "overweight" rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. JPMorgan Chase & Co. raised their price target on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, October 25th. Finally, Leerink Partners dropped their price objective on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $101.88.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the business's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.30% of the stock is currently owned by insiders.

DexCom Trading Up 0.9 %

DexCom stock traded up $0.69 during mid-day trading on Monday, hitting $78.41. 2,287,807 shares of the company's stock were exchanged, compared to its average volume of 3,899,327. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $30.63 billion, a P/E ratio of 46.95, a PEG ratio of 2.38 and a beta of 1.12. The company's 50 day simple moving average is $72.77 and its 200-day simple moving average is $85.41.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.